Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN) View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2012-2016

ABSTRACT

The purpose of this study is to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-<18 years old with immunotolerant chronic hepatitis B. Detailed Description This single arm treatment study was conducted by the pediatric centers within the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK)-sponsored Hepatitis B Research Network (HBRN). Children age 3-<18 years with immunotolerant chronic hepatitis B (CHB) infection who fulfilled the entry criteria received entecavir as monotherapy for 8 weeks and then combination therapy with entecavir and pegylated interferon by weekly subcutaneous injection until week 48. Children were to be followed for 48 weeks after discontinuation of therapy (week 96 for those who completed 48 weeks of treatment). Assessment was undertaken at baseline, weeks 4, 8, 10, 12, 14, & 16, then every 4 weeks until week 48, and then 4, 8, 12, 24,36, and 48 weeks following treatment discontinuation corresponding to weeks 52, 56, 60, 72, 84 and 96 for those who received treatment for 48 weeks. Blood work was drawn to measure markers of viral and liver disease status and for research biospecimen banking. Participants were to receive therapy until week 48 and enter 48 weeks of follow-up thereafter. Participants who experienced a sustained elevation of alanine aminotransferase (ALT) were eligible to receive treatment as recommended by their hepatologist and continued to complete the study protocol. More... »

URL

https://clinicaltrials.gov/show/NCT01368497

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "The purpose of this study is to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-<18 years old with immunotolerant chronic hepatitis B.\n\nDetailed Description\nThis single arm treatment study was conducted by the pediatric centers within the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK)-sponsored Hepatitis B Research Network (HBRN). Children age 3-<18 years with immunotolerant chronic hepatitis B (CHB) infection who fulfilled the entry criteria received entecavir as monotherapy for 8 weeks and then combination therapy with entecavir and pegylated interferon by weekly subcutaneous injection until week 48. Children were to be followed for 48 weeks after discontinuation of therapy (week 96 for those who completed 48 weeks of treatment). Assessment was undertaken at baseline, weeks 4, 8, 10, 12, 14, & 16, then every 4 weeks until week 48, and then 4, 8, 12, 24,36, and 48 weeks following treatment discontinuation corresponding to weeks 52, 56, 60, 72, 84 and 96 for those who received treatment for 48 weeks. Blood work was drawn to measure markers of viral and liver disease status and for research biospecimen banking. Participants were to receive therapy until week 48 and enter 48 weeks of follow-up thereafter. Participants who experienced a sustained elevation of alanine aminotransferase (ALT) were eligible to receive treatment as recommended by their hepatologist and continued to complete the study protocol.", 
    "endDate": "2016-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01368497", 
    "keywords": [
      "clinical trial", 
      "chronic HBV infection", 
      "safety", 
      "efficacy", 
      "drug", 
      "pegylated interferon", 
      "child", 
      "chronic hepatitis", 
      "treatment study", 
      "National Institute of Diabetes", 
      "National Institute of Diabetes and Digestive and Kidney Disease", 
      "research network", 
      "CHB", 
      "infection", 
      "entry criterion", 
      "monotherapy", 
      "combination therapy", 
      "subcutaneous injection", 
      "discontinuation", 
      "therapy", 
      "assessment", 
      "baseline", 
      "treatment discontinuation", 
      "blood", 
      "marker", 
      "liver disease", 
      "biospecimens", 
      "sustained elevation", 
      "ALT", 
      "study protocol"
    ], 
    "name": "Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01368497"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00010.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.17635.36", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.419635.c", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.21107.35", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.42327.30", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.267313.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.240741.4", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.413077.6", 
        "type": "Organization"
      }
    ], 
    "startDate": "2012-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/bf02088471", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009089600", 
          "https://doi.org/10.1007/bf02088471"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02088471", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009089600", 
          "https://doi.org/10.1007/bf02088471"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01368497"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01368497'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01368497'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01368497'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01368497'


 

This table displays all metadata directly associated to this object as RDF triples.

65 TRIPLES      16 PREDICATES      52 URIs      39 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01368497 schema:about anzsrc-for:3053
2 schema:description The purpose of this study is to determine the safety and efficacy of treatment using a combination of drugs (entecavir and pegylated interferon) in children ages 3-<18 years old with immunotolerant chronic hepatitis B. Detailed Description This single arm treatment study was conducted by the pediatric centers within the National Institute of Diabetes Digestive and Kidney Diseases (NIDDK)-sponsored Hepatitis B Research Network (HBRN). Children age 3-<18 years with immunotolerant chronic hepatitis B (CHB) infection who fulfilled the entry criteria received entecavir as monotherapy for 8 weeks and then combination therapy with entecavir and pegylated interferon by weekly subcutaneous injection until week 48. Children were to be followed for 48 weeks after discontinuation of therapy (week 96 for those who completed 48 weeks of treatment). Assessment was undertaken at baseline, weeks 4, 8, 10, 12, 14, & 16, then every 4 weeks until week 48, and then 4, 8, 12, 24,36, and 48 weeks following treatment discontinuation corresponding to weeks 52, 56, 60, 72, 84 and 96 for those who received treatment for 48 weeks. Blood work was drawn to measure markers of viral and liver disease status and for research biospecimen banking. Participants were to receive therapy until week 48 and enter 48 weeks of follow-up thereafter. Participants who experienced a sustained elevation of alanine aminotransferase (ALT) were eligible to receive treatment as recommended by their hepatologist and continued to complete the study protocol.
3 schema:endDate 2016-12-01T00:00:00Z
4 schema:keywords ALT
5 CHB
6 National Institute of Diabetes
7 National Institute of Diabetes and Digestive and Kidney Disease
8 assessment
9 baseline
10 biospecimens
11 blood
12 child
13 chronic HBV infection
14 chronic hepatitis
15 clinical trial
16 combination therapy
17 discontinuation
18 drug
19 efficacy
20 entry criterion
21 infection
22 liver disease
23 marker
24 monotherapy
25 pegylated interferon
26 research network
27 safety
28 study protocol
29 subcutaneous injection
30 sustained elevation
31 therapy
32 treatment discontinuation
33 treatment study
34 schema:name Clinical Trial of Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic HBV Infection (HBRN)
35 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01368497
36 schema:sdDatePublished 2019-03-07T15:24
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher N96894dbb9bab4b74825bf8bf65e113ff
39 schema:sponsor https://www.grid.ac/institutes/grid.17635.36
40 https://www.grid.ac/institutes/grid.21107.35
41 https://www.grid.ac/institutes/grid.240741.4
42 https://www.grid.ac/institutes/grid.267313.2
43 https://www.grid.ac/institutes/grid.413077.6
44 https://www.grid.ac/institutes/grid.419635.c
45 https://www.grid.ac/institutes/grid.42327.30
46 schema:startDate 2012-09-01T00:00:00Z
47 schema:subjectOf sg:pub.10.1007/bf02088471
48 schema:url https://clinicaltrials.gov/show/NCT01368497
49 sgo:license sg:explorer/license/
50 sgo:sdDataset clinical_trials
51 rdf:type schema:MedicalStudy
52 N96894dbb9bab4b74825bf8bf65e113ff schema:name Springer Nature - SN SciGraph project
53 rdf:type schema:Organization
54 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
55 rdf:type schema:DefinedTerm
56 sg:pub.10.1007/bf02088471 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009089600
57 https://doi.org/10.1007/bf02088471
58 rdf:type schema:CreativeWork
59 https://www.grid.ac/institutes/grid.17635.36 schema:Organization
60 https://www.grid.ac/institutes/grid.21107.35 schema:Organization
61 https://www.grid.ac/institutes/grid.240741.4 schema:Organization
62 https://www.grid.ac/institutes/grid.267313.2 schema:Organization
63 https://www.grid.ac/institutes/grid.413077.6 schema:Organization
64 https://www.grid.ac/institutes/grid.419635.c schema:Organization
65 https://www.grid.ac/institutes/grid.42327.30 schema:Organization
 




Preview window. Press ESC to close (or click here)


...